Pfizer Inc. (PFE) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is modestly constructive — consensus is a manageable bar (revenue ~$14.4B, adj. EPS ~$0.68) and the non-COVID business continues to outperform, but the single biggest swing factor is whether Vyndaqel family revenue holds up against IRA-driven net price erosion and whether Padcev's MIBC launch momentum accelerates as expected.

Heading into the Q2 2026 print, the bar looks achievable: consensus sits at ~$14.4B in revenue and ~$0.68 in adjusted diluted EPS, both below Q1 2026 actuals ($14.5B / $0.75), reflecting typical seasonal softness and COVID back-half weighting. Management reaffirmed full-year guidance ($59.5–$62.5B revenue; $2.80–$3.00 adj. EPS) at Q1 earnings and again via 8-K on June 18 following the CFO transition, signaling no deterioration in the underlying business. Estimate revisions have been broadly stable since the Q1 print, with the FY2026 adj. EPS consensus at ~$2.94 — near the midpoint of guidance — suggesting the Street is not pricing in meaningful upside or downside. The stock has underperformed both XLV (+11.7%) and XBI (+10.1%) since the Q1 print, declining ~5.4%, driven by the CFO departure announcement (June 18) and sector rotation into higher-beta biotech rather than any fundamental deterioration; at ~$25, PFE trades at roughly 8.5x 2026 consensus EPS, a meaningful discount to large-cap pharma peers. The key wildcard is the SigVie-002 (sigvotatug vedotin) Phase III OS readout in 2L NSCLC, which management has guided for midyear 2026 — a positive result would be the single largest re-rating catalyst for the stock and could materially shift out-year estimates.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-moderate bar — Q2 2026 revenue of ~$14.4B implies only modest YoY growth and is below Q1 actuals, while adj. EPS of ~$0.68 is well below Q1’s $0.75. Vyndaqel family revenue trajectory is the bigger swing factor given IRA net price headwinds; Padcev’s MIBC launch ramp is the key upside driver.

Table 1 — Current Quarter Snapshot (Q2 2026)

Sources: Visible Alpha consensus and actuals data; Pfizer Q1 2026 Earnings Release (May 5, 2026); Pfizer Q1 2026 Earnings Call transcript.

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Total Revenue & Adj. Diluted EPS)

Pattern: PFE has beaten adj. EPS consensus in 7 of the last 8 quarters (the lone miss was Q1 2025 on revenue only), with EPS beats averaging well above 30% — a consistent pattern of conservative guidance and cost discipline that sets a low bar for the bottom line. Revenue beats have been more variable, driven by COVID product lumpiness.

Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been unchanged since the December 2025 initial issuance and was reaffirmed twice (Q1 earnings May 5 and 8-K June 18 post-CFO departure); tone is constructive but deliberately conservative, with the CFO explicitly signaling the company “derisked delivery without raising guidance” after a strong Q1.

Sources: Pfizer Financial Guidance Call (Dec 16, 2025); Pfizer Q1 2026 Earnings Call & Release (May 5, 2026); Pfizer 8-K (June 18, 2026) — CFO transition and guidance reaffirmation.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been broadly stable since the Q1 print — FY2026 revenue consensus of ~$61.8B sits near the guidance midpoint ($61.0B), and adj. EPS of ~$2.94 is near the midpoint of $2.90, suggesting the Street is not pricing in meaningful upside. Q2 2026 estimates have drifted only marginally since the post-Q1 baseline, consistent with a low-revision environment.

5. Stock Performance

Key Takeaway: PFE has underperformed both XLV (+11.7%) and XBI (+10.1%) by a wide margin since the Q1 print (-5.4%), driven primarily by the June 18 CFO departure announcement and sector rotation into higher-beta biotech; the underperformance is sentiment/event-driven rather than fundamental, as guidance was reaffirmed simultaneously with the CFO news.

PFE vs. XLV (Health Care Select Sector ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings (May 5, 2026). Source: Yahoo Finance.

Key events since Q1 earnings (May 5, 2026):

• May 5, 2026: Q1 2026 earnings beat on both revenue and adj. EPS; guidance reaffirmed. Stock rose modestly on the day.
• June 18, 2026: CFO Dave Denton announced departure (effective Aug 15); Cecile Guegan named Interim CFO. Guidance simultaneously reaffirmed via 8-K. Stock sold off ~3% on the day, underperforming XLV.
• June 23–26, 2026: Continued weakness as sector rotation favored biotech (XBI +5% over the same period); PFE declined to ~$23.67 intraday low.
• Late June – July 2026: Partial recovery to ~$25 range as biotech rotation moderated; PFE remains a laggard vs. XLV which benefited from strong large-cap pharma earnings (JNJ, AZN, ABBV all beat and raised).

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the CFO departure (June 18), which created near-term uncertainty despite simultaneous guidance reaffirmation; the Vyndamax patent settlement (April 28) remains the most structurally significant positive, extending effective U.S. exclusivity to mid-2031 and underpinning management’s high single-digit revenue CAGR target starting 2029.

• June 18, 2026 — CFO Dave Denton Departure: Denton announced resignation effective August 15 for a consumer goods opportunity; Cecile Guegan (SVP Finance, Global Biopharma) named Interim CFO. Pfizer simultaneously reaffirmed all FY2026 guidance components via 8-K. Implication: Near-term uncertainty around financial messaging heading into Q2 earnings; Guegan will be presenting her first quarterly results as Interim CFO on August 4.
• April 28, 2026 — Vyndamax Patent Settlement: Pfizer settled patent infringement suits with Dexcel, Hikma, and Cipla, extending effective U.S. exclusivity for Vyndamax to June 1, 2031 (subject to Apotex litigation outcome). Management quantified the impact: total LOE burden reduced from ~$17B to ~$14–15B through 2030; high single-digit 5-year revenue CAGR starting 2029 now explicitly guided. Implication: Most structurally significant positive development in the past year; materially changes the post-2028 growth narrative.
• May 5, 2026 — Q1 2026 Earnings Beat & Guidance Reaffirmation: Revenue of $14.5B (+5% YoY, +2% operationally) and adj. EPS of $0.75 both exceeded consensus. Launched/acquired products grew 22% operationally. CFO signaled the company “derisked delivery without raising guidance.” Implication: Sets a constructive tone for Q2; management’s near-raise signal suggests FY guidance has upside if COVID seasonality plays out as expected.
• May 2026 — Padcev EV-304 Data at ASCO GU: Padcev + pembrolizumab reduced risk of recurrence or death by ~50% in cisplatin-eligible muscle-invasive bladder cancer (MIBC). Combined with EV-303 data, positions the regimen as potential new standard of care in MIBC regardless of cisplatin eligibility. Implication: Significant upside driver for Padcev revenue beyond the current la/mUC indication; MIBC launch momentum is a key Q2 watch item.
• June 2026 — Goldman Sachs Healthcare Conference (Bourla): Bourla introduced a candid distinction between R&D technical success rate (top quartile) vs. commercial/strategic focus (historically mediocre); framed current pipeline reshaping as fixing product selection, not capability. Also provided specific AI benefit timeline: scaling H2 2026, major decisions by year-end, AI-native org by end-2027, financial benefits in 2028. Implication: More self-critical and analytically precise framing than prior quarters; signals management is actively addressing the Street’s pipeline credibility concerns.
• June 2026 — Innovent Biologics Oncology Collaboration: Strategic collaboration covering 12 cancer programs (8 Innovent-originated early-stage ADCs/multispecifics + 4 Pfizer-proposed discovery programs). Innovent handles Phase I; Pfizer leads global development thereafter. Implication: Accelerates Pfizer’s ADC pipeline depth at lower cost; consistent with Bourla’s China-as-scientific-superpower thesis.
• June 2026 — Jefferies Conference (Bourla on AI & Regulatory Environment): Bourla set internal AI transformation target of 2027 (vs. prior 2030); characterized 2025 as ‘not a good year’ for U.S. regulatory institutions but expressed confidence in corrective actions. Implication: Signals urgency on AI adoption; candid regulatory commentary is a tone shift from prior quarters.
• May 2026 — Prevnar 25 Phase 3 Pediatric Program Initiated: Pfizer initiated Phase 3 pediatric program for 25-valent pneumococcal vaccine and announced plans to advance a 35-valent adult candidate (Prevnar 35) into clinical development by end-2026. Implication: Extends Prevnar franchise runway; positive pipeline execution signal.
• March 2026 — Lyme Disease Vaccine (VALOR Trial): Phase 3 VALOR trial for LB6V/VLA15 (co-developed with Valneva) demonstrated strong efficacy but did not meet the primary statistical criterion in the first pre-specified analysis. Pfizer proceeding with regulatory submissions given clinically meaningful efficacy. Implication: Mixed signal; regulatory path uncertain but management is pressing forward.
• Ongoing — SigVie-002 (Sigvotatug Vedotin) Phase III OS Readout: 2L NSCLC monotherapy readout vs. docetaxel confirmed on track for midyear 2026. Protocol amended to concentrate all statistical alpha on OS (no PFS fallback). Implication: Largest binary catalyst for the stock; a positive result would be the single biggest re-rating event and could make SV the largest oncology product in Pfizer’s portfolio.

7. Peer Commentaries — Read-Throughs (Last 60 Days, Q2 2026 Relevant)

Key Takeaway: Peer Q2 2026 earnings (JNJ, AZN, ABBV, BMY, GSK) and conference commentary (AMGN, MRK) collectively signal a healthy large-cap pharma demand environment with strong oncology execution, robust Eliquis demand, and continued ATTR/tafamidis competitive dynamics — all read-throughs that are net positive for PFE’s Q2 setup. The CFO transition is the idiosyncratic risk that peers cannot inform.

Note: Only commentary from peers’ Q2 2026 earnings calls (reporting current quarter results) and post-Q1 2026 conference appearances (commenting on Q2 2026 trends) are included below. Prior-quarter earnings commentary has been excluded per the user’s instruction.

Johnson & Johnson (JNJ) — Q2 2026 Earnings (July 15, 2026)

• Bladder Cancer / Padcev Read-Through (Positive): JNJ’s INLEXZO (intravesical ADC) in non-muscle invasive bladder cancer (NMIBC) is seeing strong early launch momentum — post-J-code, 50% increase in providers and ~90% increase in insertions. JNJ described bladder cancer as a “$5B+ opportunity” and noted that nearly 1 in 3 eligible patients started on an INLEXZO regimen in Q2 (up from 1 in 4 in Q1). PFE read-through: Confirms strong physician engagement in bladder cancer broadly; Padcev’s MIBC launch (cisplatin-ineligible indication) is operating in a different segment (la/mUC and MIBC vs. NMIBC) but the overall bladder cancer treatment paradigm is expanding rapidly, which is a rising-tide positive for Padcev volume.
• Oncology Demand Environment (Positive): JNJ reported worldwide sales of $25.3B (+5.6% operationally) with double-digit growth ex-Stelara; 28 products/platforms each delivering >$1B annually. Darzalex grew ~18%, Carvykti +47.7%, Tecvayli +56%. PFE read-through: Broad-based oncology demand strength is a positive read-through for Pfizer’s Seagen portfolio (Padcev, Adcetris, Elrexfio), which grew 20% operationally in Q1 2026.
• Milvexian / Eliquis (Positive for PFE Eliquis): JNJ confirmed the Milvexian AFib trial readout is anticipated around year-end 2026 (event-driven). JNJ described Milvexian as a potential “$5B+ asset” targeting patients who fear bleeding with current anticoagulants. PFE read-through: Milvexian is a future competitive threat to Eliquis, but the readout is not imminent; near-term Eliquis demand remains intact. JNJ’s commentary on the large untreated AFib population (40% of eligible patients not anticoagulated) is a positive for Eliquis volume.
• Procedure Volumes / Demand Stability (Positive): JNJ explicitly stated it is “not seeing evidence of a broad-based slowdown in demand” across its portfolio; procedure volumes remain stable despite ACA subsidy concerns. PFE read-through: Supportive macro backdrop for specialty pharma demand; no evidence of patient access deterioration that would pressure Pfizer’s specialty care products.

AstraZeneca (AZN) — Q2 2026 Earnings (July 27, 2026)

• ATTR / Tafamidis Competitive Read-Through (Mixed/Negative): AZN’s Wainua (eplontersen) Phase 3 Cardio Transform trial in ATTR cardiomyopathy did NOT meet its primary endpoint of CV mortality + recurrent CV events when added on top of standard of care (including 57% on a stabilizer like tafamidis). A pre-specified subgroup showed nominal significance for Wainua monotherapy patients. PFE read-through: This is a net positive for Pfizer’s Vyndaqel/Vyndamax franchise — Wainua’s failure to demonstrate add-on benefit to stabilizers reduces the competitive threat from gene silencers in the stabilizer-treated population. Tafamidis remains the standard of care backbone, and the trial result reinforces its durability.
• Bladder Cancer / Padcev (Positive): AZN announced positive Phase 3 Volga trial results for Imfinzi in MIBC patients not eligible for cisplatin — Enfortumab vedotin (Padcev) + Imfinzi showed statistically significant and clinically meaningful improvements in both EFS and OS. PFE read-through: Directly positive for Padcev revenue — this is Pfizer’s own product (co-developed with Astellas/Seagen). The Volga data expands the addressable MIBC population and reinforces Padcev’s position as the backbone ADC in bladder cancer across cisplatin-eligible and ineligible patients.
• Oncology Revenue Growth (Positive): AZN oncology revenues grew 15% in H1 2026 to $14.1B; Enhertu +31%, Tagrisso +6%, Calquence +16%. AZN reiterated mid-to-high single-digit total revenue growth guidance for FY2026. PFE read-through: Confirms robust oncology market growth; positive backdrop for Pfizer’s Seagen franchise.
• GLP-1 / Obesity (Informational): AZN initiated Phase 3 for its oral GLP-1 (Olecko) in obesity and T2D; also initiated Phase 3 for its amylin receptor agonist (AZD 6234). PFE read-through: Competitive landscape for Pfizer’s Metsera obesity platform is intensifying; AZN’s oral GLP-1 and amylin programs are direct competitors to PFE’s berobenatide (MET-097i) and amylin combination programs. However, PFE’s monthly dosing differentiation remains intact.
• Pricing Environment / MFN (Informational): AZN noted its pricing approach has “evolved in response to MFN” with the U.S. now referencing a basket of countries; early negotiations reflect a “new reality” where wealthy nations’ prices need to rise. PFE read-through: Consistent with Pfizer’s own commentary on the Trump administration drug pricing deal (Sept 2025); no incremental negative for PFE.

AbbVie (ABBV) — Q2 2026 Earnings (July 31, 2026) & Goldman Sachs Conference (June 9, 2026)

• Eliquis Demand (Positive for PFE): BMY/ABBV’s Eliquis (co-promoted with Pfizer) delivered $4.5B in Q2 2026 revenue for BMY, up 21% YoY, driven by strong demand and market share gains following a price decrease at the start of the year. BMY raised full-year Eliquis growth guidance to 20–25% YoY. PFE read-through: Directly positive for Pfizer’s Eliquis alliance revenue line. Pfizer’s Q2 2026 Eliquis consensus of ~$2.07B appears conservative relative to the demand signal from BMY’s data; upside risk to Eliquis is the clearest positive read-through from peer earnings.
• Migraine / CGRP (Positive for Nurtec): ABBV’s migraine portfolio (Botox Therapeutic, Ubrelvy, Qulipta) delivered double-digit growth again in Q2; Qulipta received European approvals for both acute and preventive migraine. ABBV projects oral CGRPs to collectively achieve >$5B in peak sales. PFE read-through: Confirms continued strong demand in the oral CGRP class; positive for Pfizer’s Nurtec ODT, which grew 41% operationally in Q1 2026. ABBV’s commentary that only 60% of triptan writers have yet to write an oral CGRP (consistent with Pfizer’s own disclosure) confirms significant runway remains.
• Oncology / ADC Pipeline (Informational): ABBV reported total oncology revenues of >$1.6B (-2.4% operationally); highlighted Temab-A (c-Met ADC) and etentamig (BCMA TCE) as “multibillion-dollar peak potential assets” undermodeled by the Street. ABBV’s CEO noted the Street is “not modeling our oncology pipeline appropriately.” PFE read-through: Consistent with Bourla’s own commentary that the Street undermodels Pfizer’s SV and PF-4404 assets; the broader theme of Street undermodeling late-stage oncology pipelines is a positive framing for PFE’s pipeline re-rating thesis.
• Obesity / Amylin (Informational): ABBV entered obesity via a deal with Gubra for an amylin asset; noted >70% of patients fall off GLP-1 therapy after a year despite higher efficacy, making “duration and durability” the key differentiator. ABBV is studying weekly and monthly dosing. PFE read-through: Validates Pfizer’s monthly dosing differentiation thesis for berobenatide; the durability/adherence narrative is a key commercial argument for PFE’s obesity platform.

Bristol Myers Squibb (BMY) — Q2 2026 Earnings (July 30, 2026)

• Eliquis Demand (Positive for PFE): BMY reported Eliquis revenue of ~$4.5B in Q2 2026, up 21% YoY, driven by demand and market share gains. BMY raised full-year Eliquis growth guidance to 20–25%. U.S. H2 sales expected to benefit from elimination of accumulated CPI penalty in government channels. European patent expiry expected in mid-Q4 2026. PFE read-through: Strong Eliquis demand is the clearest and most direct positive read-through for Pfizer’s Q2 2026 results. The European patent expiry in mid-Q4 is a known headwind but does not affect Q2.
• Milvexian AFib Readout Delay (Positive for Eliquis Durability): BMY updated the Milvexian AFib study readout to Q1 2027 (from late 2026), citing pace of events in the event-driven study. PFE read-through: Extends the period of Eliquis’s competitive moat; no near-term threat from Milvexian to Eliquis revenue.
• Multiple Myeloma / Elrexfio (Positive): BMY’s Breyanzi grew 41% in Q2; Reblozyl +29%; Camzyos +59%. BMY noted typical summer demand patterns may moderate Breyanzi growth in Q3. PFE read-through: Strong hematology/oncology demand environment is positive for Pfizer’s Elrexfio (elranatamab) in multiple myeloma, which received positive Phase 3 readout in Q1 2026.
• ADC Pipeline (Informational): BMY highlighted encouraging Phase 3 data from two isoprene studies supporting its ADC strategy across difficult-to-treat solid tumors. PFE read-through: Confirms ADC as the dominant modality in oncology; positive backdrop for Pfizer’s Seagen ADC franchise and SV readout.

GSK — Q2 2026 Earnings (July 28, 2026)

• ATTR / Tafamidis Competitive Read-Through (Positive for PFE): GSK’s Wainua (eplontersen) failed to meet its primary endpoint in the Cardio Transform trial in ATTR cardiomyopathy on top of standard of care (including stabilizers). No treatment effect was observed in patients on stabilizer therapy at baseline. PFE read-through: Same read-through as AZN above (GSK co-developed Wainua with Ionis). Tafamidis stabilizer franchise is protected; Vyndaqel/Vyndamax competitive moat is reinforced.
• Oncology / ADC (Informational): GSK’s riserus (B7-H3 ADC) Phase 3 China study (Artemis 008) met its primary OS endpoint in 2L SCLC — first positive Phase 3 OS data for a B7H3-directed ADC in any tumor type. GSK is initiating multiple Phase 3 studies in prostate cancer and SCLC. PFE read-through: Validates ADC efficacy in SCLC; positive backdrop for Pfizer’s SV readout in NSCLC. GSK’s riserus is not a direct competitor to SV (different target, different tumor type).
• Specialty Medicines Growth (Positive): GSK specialty medicines grew 14% in Q2; vaccines grew 8%. GSK updated FY2026 guidance with sales and operating profit now expected towards the upper half of the range. PFE read-through: Broad-based specialty pharma demand strength; positive macro read-through for Pfizer’s specialty care segment.

Amgen (AMGN) — Jefferies Conference (June 4) & Goldman Sachs Conference (June 9, 2026)

• Obesity / MariTide vs. Berobenatide (Informational): AMGN expressed building confidence in MariTide as a “new paradigm” for obesity; highlighted potential for 4–6 injections per year (monthly to quarterly dosing) and the SWITCH study for patients transitioning from weekly GLP-1s. AMGN noted >50% of patients on current GLP-1s stop within a year. PFE read-through: AMGN is the most direct near-term competitor to Pfizer’s berobenatide (MET-097i) in the monthly/extended-dosing obesity segment. Bourla has explicitly noted Amgen as the only near-term monthly competitor. AMGN’s Phase 3 program is advancing, but Pfizer’s manufacturing cost-of-goods advantage (10–15x lower injection volume) remains a key differentiator. The competitive dynamic is intensifying but not yet resolved.
• Oncology / IMDELLTRA (Informational): AMGN’s IMDELLTRA (tarlatamab) is now annualizing at >$1B in SCLC; AMGN is investigating it in early-stage SCLC and maintenance settings. PFE read-through: Not a direct competitor to Pfizer’s oncology portfolio; informational only.

Merck (MRK) — Jefferies Conference (June 4, 2026)

• ADC / NSCLC (Informational): MRK highlighted Phase 3 data from OptiTROP-Lung05 (sac-TMT + Keytruda vs. Keytruda alone in NSCLC with TPS >1%), showing clinically meaningful PFS improvement and OS trend. MRK also has a PDUFA date in October for I-DXd in SCLC. PFE read-through: MRK’s ADC + PD-1 combination strategy in NSCLC is directly relevant to Pfizer’s SV readout context. If MRK’s sac-TMT + Keytruda shows strong data, it raises the competitive bar for SV in NSCLC but also validates the ADC + checkpoint combination approach that Pfizer is pursuing with PF-4404 (PD-1/VEGF bispecific) + Seagen ADCs.
• Bladder Cancer (Informational): MRK has Phase 2 studies ongoing in bladder cancer for INT (individualized neoantigen therapy) in combination with pembrolizumab. PFE read-through: Early-stage; not a near-term competitive threat to Padcev.

Peer Read-Through Summary Table

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by senior insiders since Q1 earnings — the only Form 4 activity is routine phantom stock unit accruals (compensation-related, code ‘A’) for the CEO and directors, plus one small open-market sale by the SVP & Controller (2,000 shares, ~$50K). The absence of discretionary buying or selling by the CEO or CFO is notable but not alarming given the CFO transition.

Source: SEC Form 4 filings (Insider Transaction Data). Open-market transactions only (Form 4 codes P/S) plus compensation accruals (code A) shown for completeness. All Bourla and director ‘A’ transactions are phantom stock unit accruals under deferred compensation plans — these are not open-market purchases and carry no signal value. The only open-market transaction is DAmico’s 2,000-share sale on June 9, 2026, which is small in size and not flagged as part of a 10b5-1 plan in the filing.

Overall assessment: No notable insider buying or unusual selling activity. The absence of open-market purchases by the CEO or other senior executives at current depressed price levels (~$25, near multi-year lows) is a mild negative signal, but the CFO transition and typical pre-earnings blackout window likely explain the inactivity. Nothing in the insider data contradicts the constructive fundamental setup.